About the Editors
David Sulzer, PhD, Columbia University, New York, USA
David Sulzer is a professor in the Departments of Psychiatry, Pharmacology, and Neurology at Columbia University. He is a member of the Parkinson’s Disease Foundation Research Center at Columbia and is a member of the Foundation’s Scientific Advisory Board. His laboratory investigates the interaction between the synapses of the cerebral cortex and the basal ganglia, including the dopamine system, in habit formation, planning, decision making, and diseases of the system. His lab has developed the first means to optically measure neurotransmission methods and has introduced new hypotheses of neurodegeneration in Parkinson's disease and habit learning. Their work has made several fundamental contributions to understanding the mechanism of action of basal ganglia and dopamine neurons, brain cells of central importance in Parkinson's and Huntington's disease, as well as schizophrenia and drug addiction. His work increased the understanding of the life cycle of synaptic vesicles, cellular structures that package neurotransmitter release.
K Ray Chaudhuri, MD FRCP DSc, King's College London, UK
K Ray Chaudhuri is a Professor in Neurology/Movement Disorders at King's College London. He is the Medical Director of the National Parkinson Foundation International Centre of Excellence at King's College London. He sits on the Nervous Systems Committee of UK Department of Health, National Institute of Health Research, and serves as member of the Scientific Programme Committee of the International Parkinson’s and Movement Disorders Society having been Chairman of the Liaison and Appointments Committee since 2010. He is the Chairman of the newly-formed MDS non motor study group and member of the WFN organizational committee, the task force of practice parameter group for PD and RLS and, more recently, Non Motor Symptoms of Parkinson’s, American Academy Neurology. Prof. Ray Chaudhuri is the author of 265 papers including reviews, book chapters and over 300 published peer-reviewed abstracts, co-editor of four books on Parkinson’s disease and Restless Legs Syndrome. His major research interests are clinical aspects of non motor symptoms of Parkinson’s disease, non motor subtyping, and effect of continuous drug delivery and other treatment on non motor aspects of PD and restless legs syndrome. He has a specific interest in Parkinsonism in minority ethnic groups, pain and sleep problems in Parkinson’s disease.
Stanley Fahn, MD, Columbia University, New York, USA
Stanley Fahn, MD is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University. He has participated in clinical trials of many pharmacotherapeutic agents for PD. He developed a clinical trial to study the effect of levodopa therapy on the natural history of PD, which is funded by NIH. He co-directed the first controlled surgical trial for fetal tissue transplantation for patients with advanced PD. He has co-edited a number of volumes related to PD, dystonia, myoclonus and other movement disorders. Along with Dr. Ira Shoulson, Dr. Fahn was a co-founder of the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conduct controlled clinical trials on the prevention and treatment of Parkinson's disease. He was co-principal investigator or Steering Committee member of several PSG multi center controlled clinical trials: DATATOP evaluated antioxidant agents in the early stages of the disease; trials testing lazabemide, a specific reversible MAO B inhibitor, in early PD; trials testing pramipexole, a dopamine agonist, in early PD and many more.
Stephanie Cragg, MA DPhil, Professor of Neuroscience, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
Professor Stephanie Cragg’s laboratory focuses on understanding dopamine neurotransmission in the basal ganglia, control by striatal circuits, and dysfunction in neurodegenerative disorders and drug addiction. Steph works at the forefront of understanding neuronal signalling dynamics in relation to the biology of neurodegenerative disease and addiction. Her research explores the regulation of neurons throughout the region of the brain termed basal ganglia, including understanding the function and dysfunction of the dopaminergic neurons which die off in Parkinson's. They are the founding group of the Oxford Parkinson's Disease Centre. Her first degree was in Natural Sciences at the University of Cambridge, and her DPhil explored neuronal dendrite function at the University of Oxford and New York University as a Mary Goodger Scholar. During Junior Research Fellowships and a Beit Memorial Fellowship in Oxford, and further research at NYU and the University of North Carolina, Dr. Cragg developed her expertise in real-time electrochemical detection and established the program of study into how dopamine transmission is governed in the brain. She joined the Department of Physiology, Anatomy and Genetics in 2006 to take up post as University Lecturer and Tutor for Medicine at Christ Church.
Prof. Simon Lewis, Associate Professor, Brain & Mind Research Institute, Sydney Medical School, Australia
Prof Simon Lewis is an NHMRC-ARCDementia Fellow who works as a Consultant Neurologist at the Royal Prince Alfred Hospital and is Professorof Cognitive Neuroscience at the University of Sydney. He is the Director of the Parkinson's Disease Research Clinic at the Brain & Mind Research Institute and heads the NSW Movement Disorders Brain Donor program. He has published over 100 peer review papers, 2 books and 2 book chapters and has attracted funding from the NHMRC, ARC and Michael J Fox Foundation to support his research interests targeting quality of life in PD. In addition to this research, he previously sat on theBoard of Parkinson's NSW. He recently led the nationwide 'DASH to the InfoLine' campaign aiming to raise awareness and reduce stigma in PD andheaded the first trial to evaluate community based Parkinson's nurse specialists in Australia.
Pablo Martinez-Martin, MD, PhD, Instituto de Salud Carlos III, Madrid, Spain
Scientist Researcher of the Spanish Public Boards of Research at the National Center of Epidemiology, Carlos III Institute of Health (ISCIII) and Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED – ISCIII), Madrid, Spain. Pablo Martinez-Martin is a Neurologist and the Scientific Director at the Alzheimer’s Disease Research Unit, CIEN Foundation–Reina Sofia Foundation. He is also a member of the Centre of Excellence for Biomedical Research on Neurodegenerative Diseases (CIBERNED) and Professional Researcher of the Spanish Public Boards of Research in the Area of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Health (Ministry of Science and Innovation), Madrid, Spain. His interest in research is focused on movement disorders, especially Parkinson’s disease, assessment instruments, outcomes research, dementia, prion diseases and the burden placed on caregivers. He is a member (Steering Committee, Expert Consultant, or Principal Investigator) of several Movement Disorder Society Task Forces for the revision of rating scales in Parkinson’s disease (Unified Parkinson’s Disease Rating Scale; anxiety, apathy and anhedonia; fatigue; dyskinesia; fluctuations) and international collaborative studies (Scale for Outcomes of Parkinson’s disease – PROfiling PARKinson’s disease [SCOPA-Propark], Non-Motor Symptoms Group, Estudio longitudinal de pacientes con enfermedad de Parkinson [ELEP/EILEP]).
Andrew B. Singleton, Ph.D., NIH Distinguished Investigator, Laboratory of Neurogenetics, NIA, Bethesda, Maryland, USA
Dr. Andrew Singleton is a human geneticist whose research interests focus on the genetics of neurological disease. Dr. Singleton received his B.Sc. (Hons) degree from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK where he studied genetic causes and contributors to dementia. Dr. Singleton performed his postdoctoral training at the Mayo Clinic in Jacksonville, Florida, studying the genetic basis of neurological diseases such as dystonia, ataxia, essential tremor, dysautonomia, stroke and Parkinson's disease. In 2001 he joined the NIA as an Investigator within the newly created Laboratory of Neurogenetics. Dr. Singleton's group investigates the genetic and cellular mechanisms underlying simple-Mendelian and complex neurological diseases.
Malú G. Tansey, Ph.D., Associate Professor of Physiology, Emory University School of Medicine, Atlanta, Georgia, USA
The general interests of Dr. Tansey’s laboratory include investigating the role and regulation of neuroinflammatory and immune system responses in modulating the gene-environment interactions that determine risk for development and progression of neurodegenerative and neuropsychiatric disease. Her lab employs molecular, cellular, biochemical, pharmacological, immunohistological, fixed and live-cell high-content imaging, and behavioral assays to address important mechanistic questions with the long-term goal of developing novel therapeutics for the prevention and/or treatment of chronic neurodegenerative and neuropsychiatric diseases characterized by chronic neuroinflammation.